-
公开(公告)号：US20200048341A1
公开(公告)日：2020-02-13
申请号：US16502714
申请日：2019-07-03
Applicant: Novartis AG
Inventor： Joy GHOSH , Michael ROGUSKA , Mark Anthony RUTZ , Igor SPLAWSKI , Kathrin Ulrike TISSOT-DAGUETTE
IPC: C07K16/26 , C07K16/22 , A61K39/395 , A61K45/06
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
公开(公告)号：US20190040128A1
公开(公告)日：2019-02-07
申请号：US15971250
申请日：2018-05-04
Applicant: NOVARTIS AG
Inventor： Kurt Alex HELDWEIN , Igor SPLAWSKI , Jennifer BROGDON , Joshua GOLDSTEIN , William DOLE , John TRAUGER , Chonghui ZHANG
IPC: C07K16/28 , A61P9/08 , A61P9/12 , A61P9/04 , A61K9/00 , A61K39/395 , A61K45/06 , A61P9/10 , A61K39/00 , C07K14/47
Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
-
公开(公告)号：US20210355206A1
公开(公告)日：2021-11-18
申请号：US17383319
申请日：2021-07-22
Applicant: NOVARTIS AG
Inventor： Joy Gispati GHOSH , Michael ROGUSKA , Mark Anthony RUTZ , Igor SPLAWSKI , Kathrin Ulrike TISSOT-DAGUETTE
IPC: C07K16/26 , C07K16/22 , A61K39/395 , A61K45/06
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
公开(公告)号：US20190135913A1
公开(公告)日：2019-05-09
申请号：US16130166
申请日：2018-09-13
Applicant: NOVARTIS AG
Inventor： Joy GHOSH , Mark Anthony RUTZ , Kathrin Ulrike TISSOT-DAGUETTE , Igor SPLAWSKI , Michael ROGUSKA
IPC: C07K16/26 , A61K45/06 , A61K39/395 , C07K16/22
CPC classification number: C07K16/26 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
Patent Agency Ranking
公开(公告)号：US20220213181A1
公开(公告)日：2022-07-07
申请号：US17699925
申请日：2022-03-21
Applicant: NOVARTIS AG
Inventor： Regis CEBE , Igor SPLAWSKI , John TRAUGER , Andrei Igorevich VOZNESENSKY
Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
-
公开(公告)号：US20210283262A1
公开(公告)日：2021-09-16
申请号：US16323319
申请日：2017-08-04
Applicant: NOVARTIS AG
Inventor： John DOMINY , Robert DUNN , Scott GLASER , Mark KEATING , Carla KLATTENHOFF , Igor SPLAWSKI
Abstract: The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).
-
公开(公告)号：US20180327486A1
公开(公告)日：2018-11-15
申请号：US15973225
申请日：2018-05-07
Applicant: NOVARTIS AG
Inventor： Leslie Ngozi Anuna JOHNSON , Ute JAEGER , Yong-In KIM , Christian Carsten Silvester KUNZ , Igor SPLAWSKI , Michael ROGUSKA , Joy GHOSH , Barbara BRANNETTI , Michael STEFANIDAKIS , Sha-Mei LIAO
IPC: C07K16/18 , C07K16/24 , G01N33/68 , A61K39/395
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
公开(公告)号：US20170260260A1
公开(公告)日：2017-09-14
申请号：US15354978
申请日：2016-11-17
Applicant: Novartis AG
Inventor： Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
-
公开(公告)号：US20170152313A1
公开(公告)日：2017-06-01
申请号：US15346026
申请日：2016-11-08
Applicant: NOVARTIS AG
Inventor： Kurt Alex HELDWEIN , Igor SPLAWSKI , Jennifer BROGDON , Joshua GOLDSTEIN , William DOLE , John TRAUGER , Chonghui ZHANG
IPC: C07K16/28 , A61K45/06 , A61K9/00 , A61K39/395
CPC classification number: C07K16/28 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , C07K14/4726 , C07K16/2851 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.026 seconds)
